Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of different lenalidomide dose regimens in relapsed or refractory B-cell chronic lymphocytic leukemia
2009-009836-54Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Safety. Started Jul 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-009836-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009836-54.